Clinical Trial Update: Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36 [Phase 4]

View source ↗

Summary

Clinical trial comparing incidence of preeclampsia in pregnant women receiving Tdap vaccine at 28 weeks versus 36 weeks (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pre-eclampsia

Drugs mentioned

• Tdap vaccine (Diphtheria, tetanus, and pertussis vaccine (Tdap))

Snippet

Sponsor: Institute of Arthritis Research | Conditions: Pre-Eclampsia, Diphtheria, Tetanus and Pertussis Vaccine Reaction | Phase 4 | Status: UNKNOWN